Olwyn Deignan

Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study

J. McCaffrey, P. Kelly, R. McDermott, 2021, Therapeutic advances in medical oncology.

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high-risk or node-positive prostate cancer: ENZARAD (ANZUP 1303).

M. Stockler, S. Hughes, I. Davis, 2016 .

Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304).

M. Stockler, I. Davis, F. Vera-Badillo, 2015 .